Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $167.9952W HIGH $437.41
Volume
1.01 M
Value Traded
685.43 M
Short % Float
3.56%
-5.86%Week
+22.86%1 Month
+46.84%3 Month
+98.47%6 Month
+128.18%5 Year
+819.41%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
57.76 B
EPS (TTM)
-1.33
P/E Ratio
-
Ent. Value
56.75 B
Total Shares
144.14 M
Float Shares
134.88 M
Insiders
6.43%
Institutions
92.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NTRA Catalyst Timeline
Dated clinical, regulatory and corporate events for Natera, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Natera, Inc.
159Total events
10Upcoming
31Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Breakthrough Therapy DesignationDesignation
FDA grants Breakthrough Device designation to Natera's multi-cancer early detection assay
multi-cancer early detectionsource ↗
▲First Patient DosedSignateraApprovedTrial
First patients enrolled in Signatera-guided melanoma trial
advanced or metastatic melanomasource ↗
●Trial InitiationgiredestrantTrial
AFT-70 NAVIGATE Phase III trial launched evaluating giredestrant with Signatera MRD-guided CDK4/6 inhibitor therapy
ER-positive/HER2-negative early breast cancersource ↗
▲Oral PresentationSignateraApprovedPresentation
Oral presentation of ctDNA as early predictive biomarker in locally advanced cervical cancer treated with Interlace regimen (Abstract #213)
locally advanced cervical cancersource ↗
▲FDA ApprovalSignateraApprovedFDA Decision
PMDA approves Signatera as CDx in MIBC
muscle-invasive bladder cancer (MIBC)source ↗
▲PublicationSignateraApprovedPresentation
Publication of Signatera validation data in Blood Neoplasia
lymphomasource ↗
▲Oral PresentationSignateraApprovedPresentation
Mini oral presentation of largest MRD dataset in lung cancer (1,129 patients) at WCLC 2026
resected stage 1-3 non-small cell lung cancer (NSCLC)source ↗
●Poster PresentationSignateraApprovedPresentation
Poster P2.192: ctDNA after definitive therapy ± immunotherapy and association with survival outcomes
locally advanced unresectable NSCLCsource ↗
●Oral PresentationPresentation
Mini oral MO05.07: KRAS G12C predicts superior outcomes with 1L cemiplimab in EMPOWER-Lung 1
non-squamous aNSCLC with PD-L1 ≥ 50%source ↗
▲Partnership / LicenseCorporate
Natera and Susan G. Komen announce national partnership
breast cancersource ↗
▲Partnership / LicenseCorporate
Natera and Angiex announce collaboration to assess AGX101 response using Signatera
●Trial InitiationAGX101Trial
AGX101 Phase 1 trial currently enrolling patients
unresectable, locally advanced or metastatic solid tumorssource ↗
▲First Patient DosedKUP-101Trial
First patient dosed in Phase 1 trial of KUP-101
advanced skin cancerssource ↗
▲Enrollment UpdateKUP-101Trial
Safety committee approves ongoing enrollment in Phase 1 trial
advanced skin cancerssource ↗
●PMDA MilestoneSignateraApprovedEx-US Regulatory
Submitted application to PMDA for Signatera as CDx in MIBC
muscle-invasive bladder cancersource ↗
▲PublicationSignateraApprovedPresentation
Publication of Signatera vs AMERK study in JAMA Dermatology
Merkel cell carcinomasource ↗
▲Other Regulator MilestoneSignateraApprovedEx-US Regulatory
Signatera receives IVDR Class C certification in EU
multiple cancerssource ↗
▲Oral PresentationSignateraApprovedPresentation
Oral presentation at 2026 ESMO GI Congress
resected colorectal liver metastasessource ↗
▲Full ResultsSignateraApprovedClinical Data
Publication in JAMA Oncology of Signatera MRD test predicting OS benefit from ACT in resected CRLM
resected colorectal liver metastasessource ↗
▲Partnership / LicenseCorporate
Natera and Aveta Biomics announce strategic partnership for global Phase 3 registrational trial of APG-157
head and neck cancersource ↗
▲Partnership / LicenseCorporate
Natera and Eledon announce strategic partnership for Prospera monitoring in planned Phase 3 kidney transplant trial
kidney transplantsource ↗
▲Other Regulator MilestoneSignateraApprovedEx-US Regulatory
Signatera receives regulatory approval in Japan for colorectal cancer
colorectal cancersource ↗
▲BLA SubmissionSignateraApprovedRegulatory Filing
NCCN recommends ctDNA-MRD testing using Signatera in bladder cancer guideline update
bladder cancersource ↗
▲FDA ApprovalSignateraApprovedFDA Decision
Signatera approved in Japan in colorectal cancer
colorectal cancersource ↗
▲PMDA MilestoneSignateraApprovedEx-US Regulatory
PMDA approval in colorectal cancer
colorectal cancersource ↗
▲Partnership / LicenseSignateraApprovedCorporate
Collaboration with Diakonos Oncology for Signatera in refractory melanoma
refractory melanomasource ↗
◆Oral PresentationSignateraApprovedPresentation
Multiple analyses from GALAXY study in CRC on serial Signatera testing and MRD-guided decision making
colorectal cancersource ↗
▲First Patient DosedSignateraApprovedTrial
First patients enrolled in SIGNAL-ER 101 trial evaluating Signatera MRD-guided therapy in breast cancer
intermediate-risk HR+/HER2- breast cancersource ↗
▲Product LaunchPanoramaPost-Market
Launch of enhanced Panorama NIPT powered by SNP-informed deep sequencing
non-invasive prenatal testing (NIPT)source ↗
▲Enrollment MilestoneTrial
EXPAND trial enrollment surpasses 2,000 patients
single-gene noninvasive prenatal testing (NIPT)source ↗
◆Oral PresentationProsperaPresentation
Prospera featured in 17 abstracts including six oral presentations at ISHLT 2026
heart and lung transplantationsource ↗
▲Interim Analysiscemacabtagene ansegedleucelTrial
Interim futility analysis from ALPHA3 trial shows 58.3% MRD clearance with cema-cel
large B-cell lymphomasource ↗
◆Oral PresentationPresentation
Allogene to host conference call and webcast to discuss interim futility analysis
▲Interim AnalysisTrial
Positive interim futility analysis from ALPHA3 trial
large B-cell lymphomasource ↗
▲IP Litigation RulingIP / Competition
Court orders 30% ongoing royalty to Natera for MRD-related patents
▲Oral PresentationSignateraApprovedPresentation
Signatera MRD identifies breast cancer patients who can forgo surgery
breast cancersource ↗
▲PublicationSignateraApprovedPresentation
Publication in Nature Communications on Signatera in ASCC
anal squamous cell carcinomasource ↗
◆Poster PresentationSignateraApprovedPresentation
Poster: ctDNA analysis in participants with advanced ccRCC treated with first-line pembrolizumab from KEYNOTE-427
advanced clear cell renal cell carcinomasource ↗
◆Oral PresentationSignateraApprovedPresentation
Oral presentation of ctDNA-guided adjuvant atezolizumab in MIBC: exploratory analysis of ctDNA dynamics in IMvigor011
muscle-invasive bladder cancersource ↗
◆Poster PresentationSignateraApprovedPresentation
Poster: Predictive value of early ctDNA response in aUC treated with enfortumab vedotin plus pembrolizumab
advanced urothelial carcinomasource ↗
◆PublicationSignateraApprovedPresentation
INDIBLADE findings published in Nature Medicine
muscle-invasive bladder cancersource ↗
●NDA SubmissionSignateraApprovedRegulatory Filing
PMA submission to FDA based on IMvigor011
muscle-invasive bladder cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How NTRA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Natera, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NTRA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Signatera | cancers including locally advanced rectal cancer, anal squamous cell carcinoma, vulvovaginal cancer, and locally advanced cervical cancer | 2026-10-06 | 100% sensitivity; 97% specificity; 18-month progression-free survival (PFS) of 8%; 18-month overall survival (OS) of 73%; 18-month PFS was 97%; 100% sensitivity with a median lead time of 117 daysRead More | New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation OncologistsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Moshkevich SolomonOfficer (PRESIDENT, CLINICALDIAGNOSTICS) | Sell | -200 109,714 held | $411.62 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NTRA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 21.8 % (84.7 %) | 420.82 M | 1.55 M |
NTRA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-04-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NTRA ranks across every disease it competes in
Competitive Position is a premium feature
See how NTRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNTRA News
NTRA▲ +2.5%today
FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
Natera, Inc. has received Breakthrough Device designation from the FDA for its multi-cancer early detection assay. This designation is aimed at innovative technologies that improve the diagnosis of serious diseases. The recognition highlights Natera's leadership in cell-free DNA and precision medicine, potentially enhancing early cancer detection methods.
Read more →NTRA▲ +2.5%today
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
Natera, Inc. has announced the enrollment of the first patients in a new Signatera-guided interventional study targeting advanced or metastatic melanoma. This trial, sponsored by NYU Langone Health, aims to utilize Signatera technology to guide treatment escalation in patients suffering from this aggressive form of skin cancer. The study represents a significant step forward in precision medicine for melanoma treatment.
Read more →NTRA▼ -5.9%on this newsshared move
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Natera, Inc. presented new data on Signatera at the ASTRO 2026 Annual Meeting, marking its first participation in the conference. The data highlights the utility of Signatera in treatment response monitoring and risk stratification. All four abstracts presented were selected for oral presentations, showcasing the significance of the findings.
Read more →NTRAAlliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Alliance Foundation Trials and Natera have launched the AFT-70 NAVIGATE trial, a randomized phase III study. This trial aims to evaluate a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer. The collaboration seeks to enhance treatment efficacy and patient outcomes.
Read more →NTRA▲ +5.5%on this news
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Natera, Inc. has announced that its Signatera test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency as a companion diagnostic for muscle-invasive bladder cancer. This approval allows the test to assist in guiding treatment decisions for patients receiving adjuvant atezolizumab. Natera anticipates commercial availability following this approval.
Read more →NTRALargest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
Natera, Inc. has unveiled significant findings at the IASLC 2026 World Conference on Lung Cancer, showcasing the largest molecular residual disease (MRD) dataset in lung cancer history. The analysis involved 1,129 patients and highlighted the strong prognostic value of SignateraTM. This presentation underscores Natera's leadership in precision medicine.
Read more →NTRANew Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
Natera, Inc. has published new data in Blood Neoplasia, confirming the effectiveness of Signatera for minimal residual disease (MRD) assessment in lymphoma patients. This validation applies to both newly diagnosed and relapsed/refractory cases. The study highlights the limitations of traditional PET/CT scans, which have a low positive predictive value.
Read more →NTRANatera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
Natera, Inc. has formed a national partnership with Susan G. Komen® to advance breast cancer awareness and education. The collaboration will focus on increasing understanding of minimal residual disease (MRD) and promoting Natera's SignateraTM MRD test, which is supported by over 185 peer-reviewed publications across various cancer types.
Read more →NTRANatera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
Natera, Inc. has announced a collaboration with Angiex, Inc. to evaluate the response to AGX101, a Nuclear-Delivered Antibody-Drug Conjugate, using Signatera. This partnership aims to enhance cancer treatment by targeting TM4SF1-expressing tumor cells. AGX101 is currently being tested in a Phase I clinical trial.
Read more →NTRANatera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
Natera, Inc. has announced a collaboration for a Phase 1 clinical trial sponsored by Kupando Therapeutics. The trial will utilize Natera's Latitude assay to assess circulating tumor DNA dynamics in patients with advanced skin cancers. This partnership aims to enhance the understanding of molecular residual disease in the context of immunotherapy.
Read more →NTRA▲ +21.4%on this newsshared move
Natera Reports Second Quarter 2026 Financial Results
Natera, Inc. reported strong financial results for Q2 2026, with total revenues reaching $752.8 million, marking a 37.7% increase compared to the same quarter in 2025. The company's gross margin also improved, rising to 64.5%. These results highlight Natera's ongoing leadership in the field of cell-free DNA and genetic testing.
Read more →NTRANatera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Natera, Inc. has submitted an application to Japan's PMDA for the approval of its Signatera test as a companion diagnostic for muscle-invasive bladder cancer. This submission marks a strategic move to enhance Natera's presence in the Japanese market, following the earlier approval of Signatera for colorectal cancer. The approval could potentially broaden treatment options for patients in Japan.
Read more →NTRA▲ +6.2%on this news
Natera to Report its Second Quarter Results on August 6, 2026
Natera, Inc. has announced the release of its second quarter financial results for 2026, which will occur after market close on August 6, 2026. Following the release, the company will host a conference call and webcast to discuss the results. This event is scheduled for 1:30 p.m. PT (4:30 p.m. ET).
Read more →NTRASignatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
Natera, Inc. announced that its Signatera test significantly outperformed the AMERK test in predicting recurrence of Merkel cell carcinoma (MCC), as published in JAMA Dermatology. The study demonstrated that Signatera not only provided stronger predictive capabilities but also detected relapses earlier than AMERK. This advancement highlights the potential of Signatera in improving patient outcomes in MCC.
Read more →NTRAFinalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
Natera, Inc. announced a final local coverage determination (LCD) that enhances coverage for its Prospera portfolio, particularly in monitoring solid organ allograft rejection. The LCD, effective August 30, 2026, allows for six kidney tests in the first year and four tests annually for the following two years. This development is expected to significantly improve patient surveillance.
Read more →NTRANatera Announces IVDR Certification for Signatera™ Across Multiple Cancers
Natera, Inc. announced that its Signatera platform has achieved Class C certification under the European Union's In Vitro Diagnostic Regulation (IVDR). This certification is significant as it adheres to one of the most stringent regulatory frameworks for in vitro diagnostic devices. The approval is expected to bolster Natera's presence in the European market.
Read more →NTRASignatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
The article discusses the Signatera™ MRD test and its ability to predict overall survival benefits from chemotherapy in patients with resected metastatic colorectal cancer. However, the article lacks specific details and insights into the study or results. The information provided is minimal and does not elaborate on the implications of the findings.
Read more →NTRANatera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
Natera and Aveta Biomics have formed a strategic partnership to support a global Phase 3 registrational trial of APG-157, a treatment for head and neck cancer. This collaboration aims to enhance the development and potential approval of the therapy. Further details regarding the trial's design and objectives were not disclosed.
Read more →NTRANatera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
Natera and Eledon have formed a strategic partnership to utilize Prospera™ monitoring in a planned Phase 3 trial for kidney transplant patients. This collaboration aims to enhance patient monitoring and outcomes in transplantation. Further details about the trial and its objectives were not disclosed.
Read more →NTRA▲ +10.7%on this newsshared move
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
Signatera™, a product developed for colorectal cancer, has received regulatory approval in Japan. This approval marks a significant advancement in the treatment landscape for colorectal cancer patients. The introduction of Signatera™ is anticipated to provide enhanced therapeutic options and potentially improve patient outcomes in Japan.
Read more →About Natera, Inc.
Headquarters13011 MCCALLEN PASS, AUSTIN, TX, 78753
BIOPHARMAWATCH ELITE PLUS
Trade the next NTRA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime